Form 8-K - Current report:
SEC Accession No. 0001193125-26-215683
Filing Date
2026-05-11
Accepted
2026-05-11 07:10:16
Documents
11
Period of Report
2026-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apge-20260511.htm   iXBRL 8-K 50771
2 EX-99.1 apge-ex99_1.htm EX-99.1 185834
3 GRAPHIC img126220792_0.jpg GRAPHIC 79141
  Complete submission text file 0001193125-26-215683.txt   462857

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20260511.xsd EX-101.SCH 23918
14 EXTRACTED XBRL INSTANCE DOCUMENT apge-20260511_htm.xml XML 4546
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 26960841
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)